Low levels of endogenous anabolic androgenic steroids in females with severe asthma taking corticosteroids

Abstract

RationalePatients with severe asthma are dependent upon treatment with high doses of inhaled corticosteroids (ICS) and often also oral corticosteroids (OCS). The extent of endogenous androgenic anabolic steroid (EAAS) suppression in asthma has not previously been described in detail.ObjectivesTo measure urinary concentrations of EAAS in relation to exogenous corticosteroid exposure.MethodsUrine collected at baseline in the U-BIOPRED study of severe adult asthmatics (SA, n=408) was analysed by quantitative mass spectrometry. Data were compared to that of mild-to-moderate asthmatics (MMA, n=70) and healthy subjects (HC, n=98) from the same study.Measurements and Main ResultsThe concentrations of urinary endogenous steroid metabolites were substantially lower in SA than in MMA or HC. These differences were more pronounced in SA patients with detectable urinary OCS metabolites. Their dehydroepiandrosterone sulphate (DHEA-S) concentrations were<5% of those in HC, and cortisol concentrations were below the detection limit in 75% of females and 82% of males. The concentrations of EAAS in OCS-positive patients, as well as patients on high dose ICS only, were more suppressed in females than males (p-value <0.05). Low levels of DHEA were associated with features of more severe disease and were more prevalent in females (p-value <0.05). The association between low EAAS and corticosteroid treatment was replicated in 289 of the SA patients at follow-up after 12–18 months.ConclusionThe pronounced suppression of endogenous anabolic androgens in females might contribute to sex differences regarding the prevalence of severe asthma.